Intensity Therapeutics Restarts Phase 2 TNBC Trial
SHELTON, Conn., July 15, 2026 Intensity Therapeutics, Inc. has restarted patient treatment in its Phase 2 INVINCIBLE-4 clinical trial...
Pembrolizumab
Advertisement
Kelun-Biotech Reports Phase III Success for sac-TMT in NSCLC
CHENGDU, China, July 14, 2026 Kelun-Biotech has announced a major clinical milestone after its Phase III OptiTROP-Lung06 trial evaluating...
Immutep Reports Positive INSIGHT-003 Survival Data
SYDNEY, Australia, July 13, 2026 Immutep announced positive mature overall survival data from its investigator-initiated Phase 1 INSIGHT-003 trial...
Merck Announces Expanded FDA Approval for Keytruda in MIBC
SILVER SPRING, Maryland, July 10, 2026 Merck has received U.S. Food and Drug Administration (FDA) approval for Keytruda® (pembrolizumab)...
Pfizer Canada Secures PADCEV Plus KEYTRUDA Approval
KIRKLAND, Quebec, Canada, June 29, 2026 Pfizer Canada ULC announced that Health Canada has approved PADCEV® (enfortumab vedotin) in...
Advertisements
Gilead Sciences Wins FDA Approval for Trodelvy in First-Line mTNBC
FOSTER CITY, Calif., June 24, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
BioInvent’s TNFR2 Antibody BI-1808 Shows Promising Responses in Advanced CTCL at EHA 2026
LUND, Sweden, June 11, 2026 BioInvent International AB presented new clinical data from its ongoing Phase 2a study evaluating...
Merck and Gilead End KEYNOTE-D46 Study Update
RAHWAY, N.J. and FOSTER CITY, Calif., June 8, 2026 Merck (NYSE: MRK) and Gilead Sciences (Nasdaq: GILD) announced the...
Agilent Expands FDA-Approved PD-L1 Testing for KEYTRUDA Across Four Cancer Types
SANTA CLARA, Calif., June 2, 2026 Agilent Technologies announced that the U.S. Food and Drug Administration (FDA) has approved...
Anaveon Reports Promising Phase 1 ANV600 Cancer Data at ASCO 2026
BASEL, Switzerland — May 28, 2026 Anaveon announced new clinical data from its Phase 1 EXPAND-1 trial showing encouraging...
Advertisement
